JP2016520053A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520053A5
JP2016520053A5 JP2016512207A JP2016512207A JP2016520053A5 JP 2016520053 A5 JP2016520053 A5 JP 2016520053A5 JP 2016512207 A JP2016512207 A JP 2016512207A JP 2016512207 A JP2016512207 A JP 2016512207A JP 2016520053 A5 JP2016520053 A5 JP 2016520053A5
Authority
JP
Japan
Prior art keywords
seq
tumstatin
amino acid
cd137l
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520053A (ja
Filing date
Publication date
Priority claimed from CN201310162738.3A external-priority patent/CN103214584B/zh
Priority claimed from CN201310163407.1A external-priority patent/CN103232543B/zh
Application filed filed Critical
Priority claimed from PCT/CN2014/076768 external-priority patent/WO2014180288A1/zh
Publication of JP2016520053A publication Critical patent/JP2016520053A/ja
Publication of JP2016520053A5 publication Critical patent/JP2016520053A5/ja
Pending legal-status Critical Current

Links

JP2016512207A 2013-05-06 2014-05-05 腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用 Pending JP2016520053A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201310162738.3A CN103214584B (zh) 2013-05-06 2013-05-06 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
CN201310163407.1A CN103232543B (zh) 2013-05-06 2013-05-06 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用
CN201310162738.3 2013-05-06
CN201310163407.1 2013-05-06
PCT/CN2014/076768 WO2014180288A1 (zh) 2013-05-06 2014-05-05 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用

Publications (2)

Publication Number Publication Date
JP2016520053A JP2016520053A (ja) 2016-07-11
JP2016520053A5 true JP2016520053A5 (OSRAM) 2018-05-31

Family

ID=51866722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512207A Pending JP2016520053A (ja) 2013-05-06 2014-05-05 腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用

Country Status (6)

Country Link
US (1) US10875903B2 (OSRAM)
EP (1) EP2995626B1 (OSRAM)
JP (1) JP2016520053A (OSRAM)
DK (1) DK2995626T3 (OSRAM)
ES (1) ES2686968T3 (OSRAM)
WO (1) WO2014180288A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
JP7247091B2 (ja) * 2016-12-20 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
IL267861B2 (en) 2017-01-05 2025-02-01 Kahr Medical Ltd PD1-41BBL conjugated protein and methods of using the same
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
SG11202013167UA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
SG11202013170RA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof
CN116462769A (zh) * 2022-04-02 2023-07-21 广东东阳光药业有限公司 一种嵌合受体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016889A1 (en) * 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
KR100682666B1 (ko) * 1998-06-17 2007-02-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 항혈관형성 단백질 및 이들을 사용하는 방법
JP2006508635A (ja) * 2002-05-06 2006-03-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 治療用または診断用試薬を送達するためのターゲティングタンパク質
US20090221477A1 (en) * 2004-07-26 2009-09-03 Asterion Limited Linkers
WO2009086132A2 (en) * 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
CN101265482A (zh) * 2008-04-25 2008-09-17 罗以勤 重组肿瘤抑素-肿瘤坏死因子分泌型真核表达载体及其制备方法和用途
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
WO2012130471A1 (en) * 2011-04-01 2012-10-04 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
DK2744831T3 (en) * 2011-08-17 2018-03-05 Univ Colorado Regents TRANSFERRIN-TUMSTATIN-FUSION PROTEIN AND PROCEDURES FOR PREPARING AND USING THE SAME
CN103232543B (zh) * 2013-05-06 2014-12-03 中国药科大学 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用
CN103214584B (zh) * 2013-05-06 2014-07-09 中国药科大学 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用

Similar Documents

Publication Publication Date Title
JP2016520053A5 (OSRAM)
WO2018050039A1 (zh) 新的抗pd-1纳米抗体及其应用
WO2016188449A1 (zh) 一种针对cd47的单域抗体
JP7026906B2 (ja) 転写調節融合ポリペプチド
WO2017070943A1 (zh) 双特异性抗体、其制备方法和用途
CN105837688A (zh) 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
JP2016520053A (ja) 腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用
US20190099461A1 (en) Rna viruses for immunovirotherapy
CN114380906A (zh) 一种抗il-17a的单域抗体及其用途
CN106928363B (zh) 一种FAP纳米抗体Nb12
CN103319595A (zh) 抗人afp单链抗体以及融合抗原肽的制备方法和应用
CN101451145A (zh) 基于t细胞表位的结核基因疫苗及其制备方法和应用
WO2019109954A1 (zh) PD-1-Fc融合蛋白及其制备方法和用途
CN111410695B (zh) 基于自噬机制介导Tau蛋白降解的嵌合分子及其应用
CN103333248A (zh) 一种cd25纳米抗体、其编码序列及应用
CN106928358B (zh) 一种CD105纳米抗体Nb168
CN104672333A (zh) 一种人源ctla4融合蛋白及其制备方法和应用
CN104031134B (zh) 一种基因治疗用载体蛋白及其制备方法和用途
Qin et al. Screening and anti‐glioma activity of Chiloscyllium plagiosum anti‐human IL‐13Rα2 single‐domain antibody
CN108484770B (zh) 重组大鼠抗小鼠cd4单克隆抗体，制备方法和应用
CN108300725B (zh) 可溶性单链抗体超抗原融合基因及蛋白和其制备与应用
CN105399832A (zh) 一种无标签单链型人源双特异性抗体及其用途
CN110903402A (zh) 一种双特异性融合蛋白及其构建方法与应用
CN103789340A (zh) 一种高效制备重组人mica蛋白的方法
CN106928368B (zh) 一种FAP纳米抗体Nb57